Dieser KIR2DL3 Antikörper ist konjugiert mit PE-Cy7
Applikation
Flow Cytometry (FACS)
Aufreinigung
The antibody was purified by affinity chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.
CD158B2 antikoerper, CD158b antikoerper, GL183 antikoerper, KIR-023GB antikoerper, KIR-K7b antikoerper, KIR-K7c antikoerper, KIRCL23 antikoerper, NKAT antikoerper, NKAT2 antikoerper, NKAT2A antikoerper, NKAT2B antikoerper, p58 antikoerper, killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 antikoerper, KIR2DL3 antikoerper
Hintergrund
CD158b is expressed on natural killer cells and a subset of T cells. It is a member of the immunoglobulin superfamily containing two immunoglobulin C2-type domains. Both variants and alternative isoforms of CD158b have been reported. The interaction of CD158b with specific HLA-C antigens on a target cell (HLA-Cw1, HLA-Cw3, HLA-Cw7 alleles, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK cell and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.